ArticleAAPS PharmSciTech2025
Design of Experiments (DoE) Driven Fabrication of Surface Modified Liposomes of Olmesartan Medoxomil for Improved Oral Bioavailability.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olmesartan Medoxomil (OLM) is a prodrug of an angiotensin II receptor antagonist and a P-glycoprotein (P-gp) substrate that is converted into Olmesartan by esterases, resulting in low oral bioavailability (26%). The aim of the present study was to formulate Olmesartan Medoxomil liposomes by thin film hydration method using Vitamin E TPGS (P gp inhibitor). Initial screening of excipients was conducted using the One Factor At A Time (OFAT) approach, while optimization was performed using Box-Behnken Design (BBD). The drug-to-lipid ratio, the amount of cholesterol, and the surfactant were identified as independent variables, with vesicle size (nm) and entrapment efficiency (%) as dependent variables. Key process parameters were evaluated through OFAT analysis, and the formulation was optimized using BBD. The prepared liposomes were characterized through vesicle size (nm), zeta potential (mV), drug loading (%), Transmission Electron Microscopy (TEM), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR), and Gas Chromatography (GC), followed by in vitro dissolution and in vivo pharmacokinetic study in 12 wistar rats. The vesicle size and entrapment efficiency of the optimized formulation were found to be 112.1 nm and 98.88% respectively. In vitro drug release studies were conducted in the USP-II apparatus exhibited a biphasic release pattern compared to the marketed formulation Olmezest®10. In vivo pharmacokinetic studies in wistar rats showed a significant increase in oral bioavailability (3.23 times) of the liposomal formulation of Olmesartan Medoxomil (OLM-LIPO) in comparison to the marketed formulation Olmezest®10.
Indexed as
Identifiers
41372511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.